Our Services
Medical Information
Helpful Resources
Published on: 3/11/2026
Candida auris is not unstoppable, but it is spreading largely in healthcare settings because it survives on surfaces for weeks, is hard to identify quickly, can resist multiple antifungal drug classes, and often exploits devices like catheters and ventilators, with medically fragile patients most at risk.
Next steps center on early diagnosis and isolation, enhanced cleaning and hand hygiene, targeted antifungals such as echinocandins guided by susceptibility testing, and coordinated surveillance and reporting. There are several factors to consider that could change your best next move; see the complete details below.
Over the past decade, candida auris has emerged as one of the most concerning fungal infections in modern medicine. It has been labeled a "superbug fungus" because it can resist multiple antifungal medications and spread in healthcare settings.
But is it truly unstoppable? The short answer is no — however, it is serious, and it requires awareness, early detection, and strong infection control measures.
Let's break down what candida auris is, why it's spreading, who is at risk, and what medical science is doing about it.
Candida auris is a type of yeast (fungus). While many Candida species normally live on the skin or inside the body without causing harm, candida auris is different.
It can cause:
Unlike common yeast infections (such as oral thrush or vaginal yeast infections), candida auris primarily affects people who are already medically vulnerable.
It was first identified in 2009 in Japan. Since then, it has been reported in over 40 countries, including the United States.
There are several reasons this fungus has become a global concern.
Most infections occur in:
It spreads through:
Unlike many other fungi, candida auris can survive on surfaces for weeks. This makes infection control more challenging.
There are three main classes of antifungal drugs used to treat serious fungal infections. Some strains of candida auris are resistant to:
In rare cases, strains are resistant to all three classes.
Drug resistance makes treatment more complex and increases the importance of early identification.
Standard laboratory tests can misidentify candida auris as other, less dangerous fungi. If misidentified:
Newer diagnostic tools have improved detection, but not all healthcare facilities have access to advanced testing.
People who need:
are at higher risk.
These devices can provide a pathway for the fungus to enter the body.
During the COVID-19 pandemic, healthcare systems were overwhelmed. Infection control resources were stretched thin. This likely contributed to the spread of candida auris in some regions.
It's important to be clear: healthy individuals are at low risk.
Those most at risk include:
For the general public, casual contact in everyday life does not usually pose a significant risk.
Symptoms depend on where the infection occurs.
Because many patients already have serious medical conditions, symptoms can be subtle.
No.
Common yeast infections (like oral thrush or athlete's foot) are usually caused by Candida albicans, not candida auris.
Typical candidiasis infections are:
If you're experiencing white patches in your mouth, cracking at the corners of your lips, or unusual fungal symptoms on your hands or feet, you can quickly check what might be causing these symptoms with a free AI-powered assessment for Candidiasis (Oral, Hands and Feet) to help determine your next steps.
That said, candida auris is a different and more serious infection, mainly affecting hospitalized patients.
According to public health agencies like the CDC and WHO, candida auris can cause severe infections with mortality rates ranging from 30–60% in bloodstream infections.
However, it's important to understand:
It is serious — but not a threat to most healthy people going about daily life.
Hospitals are implementing:
Special disinfectants are required because regular cleaning products may not kill candida auris effectively.
Modern molecular tests and specialized fungal identification systems help labs detect candida auris accurately and quickly.
Faster diagnosis leads to:
First-line treatment typically involves:
If resistance is detected, doctors may adjust therapy based on susceptibility testing.
Treatment decisions are complex and should always be guided by infectious disease specialists.
Many countries now require healthcare facilities to report confirmed cases of candida auris.
This allows:
Researchers are:
The antifungal pipeline is smaller than the antibiotic pipeline, but progress is being made.
For most people, routine hygiene is sufficient.
General prevention steps:
If you or a loved one is hospitalized long-term, you can ask healthcare providers about infection control measures in place.
Concern is reasonable. Panic is not.
Key points to remember:
The fungus is challenging — but it is not unstoppable.
You should speak to a doctor promptly if:
Any infection that causes fever, chills, confusion, shortness of breath, or low blood pressure may be life-threatening and requires immediate medical attention.
If you suspect any serious or potentially life-threatening condition, seek urgent medical care and speak to a doctor right away.
Candida auris is a serious and evolving healthcare challenge, particularly in hospitals and long-term care facilities. Its resistance to antifungal medications and ability to survive on surfaces make it harder to control than many other fungi.
However:
Awareness, early detection, and proper medical care remain the most powerful tools against candida auris.
If you have concerns about fungal infections — whether mild symptoms like oral thrush or more serious signs of illness — do not ignore them. Use reputable tools to understand your symptoms, and most importantly, speak to a doctor about anything that could be serious or life-threatening.
(References)
* Seyedmousavi S, de Hoog S, Lass-Florl C. Candida auris: epidemiology, diagnosis, and management. Front Cell Infect Microbiol. 2023 Mar 1;13:1130099. doi: 10.3389/fcimb.2023.1130099. PMID: 36936306; PMCID: PMC10014603.
* Chowdhary A, Meis JF, Denning DW, Colombo AL, de Hoog S, Patil S, Kathuria S. Candida auris: A Systematic Review of Current Understanding, Global Distribution, Prevention, Control, and Future Perspectives. J Fungi (Basel). 2022 Sep 15;8(9):947. doi: 10.3390/jof8090947. PMID: 36135898; PMCID: PMC9502690.
* Mehta A, Yadav S, Chanda P, Kumar R, Prasad R. Antifungal Resistance in Candida auris: Current Perspectives and Future Directions. Antibiotics (Basel). 2023 Jul 21;12(7):1219. doi: 10.3390/antibiotics12071219. PMID: 37508083; PMCID: PMC10376189.
* Cortegiani A, Saladino E, Giarratano A, Bassetti M. Candida auris: An Emerging Multidrug-Resistant Yeast With Significant Global Health Implications. Crit Care. 2021 Oct 29;25(1):364. doi: 10.1186/s13054-021-03774-6. PMID: 34711311; PMCID: PMC8555811.
* Al-Obeid A, Almohammed H, Alosaimi RS, Alburaikan M. Candida auris: A Challenging Pathogen and Its Impact on Healthcare Systems. J Fungi (Basel). 2023 May 15;9(5):565. doi: 10.3390/jof9050565. PMID: 37233827; PMCID: PMC10221379.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.